MaxCyte to buy Akron Bio for $152M to double its revenue base
What's the deal? MaxCyte has agreed to acquire Akron BioProducts from affiliates of Arcline Investment Management for $151.8 million, extending the cell-engineering company deeper into cell-therapy manufacturing. The deal is expected to close before the end of 2026.
The terms: MaxCyte will pay $105 million in cash, about $26.8 million in stock, and $20 million in guaranteed deferred payments split across January 2028 and January 2029. It secured a credit facility of up to $75 million from MidCap FinancialDealroom has a profile for this one. Try Dealroom → to help fund the purchase.
What each side brings: Boca Raton-based Akron supplies GMP-grade reagents and materials used across cell-therapy production, from expansion through cryopreservation. MaxCyte provides platform technologies for discovering and commercialising cell therapeutics; the combined portfolio supports five commercially approved therapies.
Why now? MaxCyte posted third-quarter revenue of $10.2 million, up 49% year-on-year, and raised its full-year outlook to at least $34.5 million. Akron is expected to generate about $28 million in revenue and $7–8 million in EBITDA in 2026, nearly doubling MaxCyte's revenue base.
What's the endgame? The acquisition expands MaxCyte's recurring revenue and commercial-stage exposure. "This acquisition represents a significant step forward for us," said chief executive officer Maher Masoud, adding it would "accelerate our path to profitability."
What could go wrong? MaxCyte reported a third-quarter net loss of $4.8 million, and its route to profitability now hinges on integrating Akron and converting its commercial exposure into durable growth.
The signal: The deal reflects continued reshaping of cell-therapy manufacturing capacity. Recent moves include Made Scientific buying a GMP cell-therapy facility from ResilienceDealroom has a profile for this one. Try Dealroom → and Lonza agreeing to acquire five contract-manufacturing sites from Merck.
Read more: finanzen.ch
Image credit: Generated with Gemini